Page last updated: 2024-11-05

bamifylline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bamifylline is a synthetic derivative of theophylline, a methylxanthine compound with bronchodilator properties. It has been studied for its potential therapeutic benefits in various conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cancer. Bamifylline exhibits anti-inflammatory and immunomodulatory effects, potentially by inhibiting the release of inflammatory mediators such as histamine and leukotrienes. It also shows promising activity as an anticancer agent, inhibiting cell growth and promoting apoptosis in various cancer cell lines. However, the exact mechanisms of action of bamifylline and its clinical efficacy remain under investigation.'

bamifylline: RN given refers to parent cpd; structure; selective A1 adenosine receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16229
CHEMBL ID2110760
CHEBI ID135605
SCHEMBL ID219043
MeSH IDM0049349

Synonyms (42)

Synonym
8-benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)-1,3-dimethyl-1h-purine-2,6(3h,7h)-dione
bamifylline
7-{2-[ethyl(2-hydroxyethyl)amino]ethyl}-1,3-dimethyl-8-(phenylmethyl)-3,7-dihydro-1h-purine-2,6-dione
2016-63-9
D07491
bamifylline (inn)
8-benzyl-7-2-(ethyl(2-hydroxyethyl)amino)ethyltheophylline
bamiphylline
bamifyllinum [inn-latin]
bamifyllin
benzetamophylline
bamifylline [inn:ban]
bamifilina [inn-spanish]
CHEBI:135605
8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione
FT-0650781
NCGC00182061-02
7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-3,7-dihydro-1,3-dimethyl-8-(phenylmethyl)-1h-purine-2,6-dione
bamifilina
unii-zty15d026h
bamifyllinum
zty15d026h ,
SCHEMBL219043
1h-purine-2,6-dione, 7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)-3,7-dihydro-1,3-dimethyl-8-(phenylmethyl)-
bax-2739z free base
bamifylline [inn]
ac-3810 free base
bamifylline [who-dd]
bamifylline [mi]
8-benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline
CHEMBL2110760
VVUYEFBRTFASAH-UHFFFAOYSA-N
8012 cb
8-benzyl-7-(2-[ethyl(2-hydroxyethyl)amino]ethyl)-1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione #
8-benzyl-7-[2-[ethyl-(2-hydroxyethyl)amino]ethyl]theophylline
DTXSID0022642
SR-01000883957-1
sr-01000883957
BCP16019
Q4853500
DB13203
ethylenediaminetetraaceticaciddisodiummagnesiumsalttetrahydrate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In addition, we assessed the risk of adverse events by normalising data on safety as a function of person-weeks."( Efficacy and safety profile of xanthines in COPD: a network meta-analysis.
Barnes, PJ; Calzetta, L; Cazzola, M; Criner, GJ; Gabriella Matera, M; Martinez, FJ; Papi, A, 2018
)
0.48

Dosage Studied

The active metabolite of bamifylline (AC119) might contribute to the bronchodilator activity of this drug.

ExcerptRelevanceReference
" We did not observe facts suggesting a possible cumulative effect of the drug, when taken at a dosage of 3 times 900 mg regularly spread over the day."( [Ventilatory effect and side effects of oral bamifylline].
Minette, A, 1978
)
0.52
" Very low plasma levels of bamifylline were observed at the end of the dosing intervals in 50% of the cases; this observation does not necessarily invalidate the efficacy of this dosage regimen because the active metabolite of bamifylline (AC119) might contribute to the bronchodilator activity of this drug."( Pharmacokinetics of bamifylline during chronic therapy.
Cerretani, D; Fusillo, M; Moltoni, L; Segre, G; Urso, R, 1990
)
0.9
" In studies on man, samples of plasma and lung tissue were obtained during surgery in subjects affected by pulmonary neoplasia and previously subjected to therapy with bamifylline according to the usual dosage scheme."( Evidence of pulmonary tropism of bamifylline and its main active metabolite.
Acerbi, D; Bonati, L; Botta, GC; Capelli, P; Rondelli, I; Schiantarelli, P, 1989
)
0.75
") for 15 days, while the second group received placebo with the same oral dosage regimen."( Effect of bamiphylline on tracheobronchial mucus clearance in subjects with smokers' simple chronic bronchitis.
Amir, E; Baglioni, S; Palumbo, R; Todisco, T, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (38.00)18.7374
1990's21 (42.00)18.2507
2000's7 (14.00)29.6817
2010's3 (6.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.81 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index48.45 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (27.27%)5.53%
Reviews4 (7.27%)6.00%
Case Studies4 (7.27%)4.05%
Observational0 (0.00%)0.25%
Other32 (58.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]